Physician profile
Sera Ramadan
NPI 1497141071
$1,316.23
in general payments reported to CMS, 2019-2025
10 companies · $80.10 in 2025
The $80.10 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $121 · 2021: $122 · 2022: $66.61 · 2023: $295 · 2024: $100 · 2025: $80.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $475.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $391.03 | 2019-2023 | Lifevest |
| Novo Nordisk INC | $310.67 | 2023-2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $249.34 | 2019 | |
| Avanir Pharmaceuticals, INC. | $124.98 | 2019 | |
| Pfizer INC. | $82.74 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $71.31 | 2020-2023 | |
| Rhythm Pharmaceuticals, INC. | $26.79 | 2024 | Imcivree |
| Lilly USA, LLC | $26.32 | 2025 | Zepbound, Mounjaro |
| Cipher Pharmaceuticals US LLC | $16.65 | 2025 | Spinosad, Natroba |
| Vbi Vaccine (Delaware) INC. | $16.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sera Ramadan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.